[1]
R. Kizlaitienė, N. Giedraitienė, I. Sereikė, J. Liutkienė, L. Leščinskienė, and G. Kaubrys, “Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic”, NS, vol. 24, no. 2(84), pp. 100–104, Jun. 2020, doi: 10.29014/ns.2020.13.